Taysha Gene Therapies, Inc. Finance Lease, Liability, to be Paid, Year Three
Taysha Gene Therapies, Inc. (TSHA) had Finance Lease, Liability, to be Paid, Year Three of $325.00 thousand as of 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree · last filed 2024-03-19
- 2023-12-31: Finance Lease, Liability, to be Paid, Year Three $325.00K.
- 2023-09-30: Finance Lease, Liability, to be Paid, Year Three $399.00K.
- 2023-06-30: Finance Lease, Liability, to be Paid, Year Three $399.00K.
- 2023-03-31: Finance Lease, Liability, to be Paid, Year Three $399.00K.
| Period end | Finance Lease, Liability, to be Paid, Year Three |
|---|---|
| 2023-12-31 | $325.00K 10-K · filed 2024-03-19 |
| 2023-09-30 | $399.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $399.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $399.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $454.00K 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |